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Background: Denosumab is effective for osteoporosis, but discontinuation leads to rapid reversal 
of its therapeutic effect. 
Objective: To estimate the risk for fracture among users of denosumab who delayed subsequent 
doses compared with users who received doses on time. 
Design: Population-based cohort study. 
Setting: The Health Improvement Network U.K. primary care database, 2010 to 2019. 
Patients: Persons aged 45 years or older who initiated denosumab therapy for osteoporosis. 
Measurements: Observational data were used to emulate an analysis of a hypothetical trial with 
3 dosing intervals: subsequent denosumab injection given within 4 weeks after the 
recommended date (“on time”), delay by 4 to 16 weeks (“short delay”), and delay by more than 
16 weeks (“long delay”). The primary outcome was a composite of all fracture types at 6 months 
after the recommended date. Secondary outcomes were major osteoporotic fracture, vertebral 
fracture, hip fracture, and nonvertebral fracture. 
Results: Investigators identified 2594 patients initiating denosumab therapy. The risk for 
composite fracture over 6 months was 27.3 in 1000 for on-time dosing, 32.2 in 1000 for short 
delay, and 42.4 in 1000 for long delay. Compared with on-time injections, short delay had a 
hazard ratio (HR) for composite fracture of 1.03 (95% CI, 0.63 to 1.69) and long delay an HR of 
1.44 (CI, 0.96 to 2.17) (P for trend = 0.093). For vertebral fractures, short delay had an HR of 1.48 
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(CI, 0.58 to 3.79) and long delay an HR of 3.91 (CI, 1.62 to 9.45). 
Limitation: Dosing schedules were not randomly assigned. 
Conclusion: Although delayed administration of subsequent denosumab doses by more than 16 
weeks is associated with increased risk for vertebral fracture compared with on-time dosing, 
evidence is insufficient to conclude that fracture risk is increased at other anatomical sites with 
long delay. 
Primary Funding Source: National Clinical Research Center for Orthopedics, Sports Medicine & 
Rehabilitation. 
Denosumab is an effective antiresorptive drug prescribed for the treatment of osteoporosis 
(1). Discontinuation of denosumab therapy, however, results in accelerated bone turnover, rapid 
loss of bone mineral density (BMD), and an increased rate of multiple vertebral fractures, often 
within a short off-treatment period of 2 to 10 months (that is, 8 months after the prior 
denosumab injection) (2–9). A post hoc analysis of a randomized placebo-controlled trial and its 
extension reported that withdrawing denosumab without switching to another antiresorptive 
agent was associated with higher risk for multiple vertebral fractures in the subsequent year (8). 
Another observational study showed an even more alarming reversal of benefit after denosumab 
therapy was stopped (10), which was associated with higher risk for vertebral fracture (incidence 
rate ratio [RR], 4.7 [95% CI, 2.3 to 9.6]), major osteoporotic fracture (RR, 3.2 [CI, 2.2 to 4.8]), and 
hip fracture (RR, 5.3 [CI, 2.0 to 13.9]) in the year after discontinuation. However, whether 
delaying subsequent injections beyond the recommended 6-month interval is associated with 
fractures is unknown. 
Delayed dosing of denosumab is very common in routine clinical practice (11–13). Among 
patients who had been using denosumab for several years, almost 50% had at least 1 injection 
delay of more than 4 months. Delaying the subsequent dose by several months is associated 
with reduced improvement in BMD (11). However, to our knowledge, no study has yet examined 
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the effect of denosumab delay on fracture risk. 
Because it may not be ethical to do a randomized controlled trial to address this question, we 
emulated an analysis of a hypothetical trial using observational data to examine the causal effect 
of delayed denosumab injection on fracture risk (14, 15). 
Methods 
Study Population and Design 
We used The Health Improvement Network (THIN), an electronic database of medical 
records from primary care practitioners in the United Kingdom, as the data source. This database 
contains health information on approximately 17 million patients from 790 general practices 
(16). For this study, we extracted data on demographic characteristics, diagnosis, and 
medications from 2010 to 2019. 
Through this period, primary care data were coded using the Read classification system, 
which we used to identify relevant diagnoses. The Health Improvement Network uses a drug 
dictionary based on data from the Multilex classification system (17). The scientific review 
committee of THIN approved this study (19THIN079), and informed consent was waived. 
This retrospective cohort study takes advantage of naturally occurring variation in the timing 
of denosumab administration, allowing us to examine the effect of this variation on fracture risk 
in routine clinical settings. We emulate a hypothetical randomized controlled trial (the “target 
trial”) comparing 3 dosing intervals for subsequent denosumab injections (on time, short delay, 
and long delay) using observational data (Appendix Table 1, available at Annals.org) (18). Target 
trial emulation is a design framework for observational research that reduces bias and better 
aligns results with those of actual randomized controlled trials (14). Appendix Table 1 provides 
details on the specification of the target trial and its emulation using observational data. 
Study Cohort 
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This study included injection data from persons aged 45 years or older who initiated 
denosumab therapy for the management of osteoporosis between 2010 and 2019. We identified 
denosumab dosages of 60 mg subcutaneously every 6 months. We excluded persons who had 
only 1 denosumab prescription record, received the subsequent injection within 150 days after 
the prior dose, or also used any other antiosteoporosis drugs (estrogen, selective estrogen 
receptor modulators, alendronate, risedronate, ibandronate, zoledronic acid, other 
bisphosphonates, or teriparatide). Patients were censored when they switched to another 
potent antiosteoporosis medication or discontinued denosumab therapy (6 months after the last 
dose). 
To improve statistical efficiency, we did the study at the injection level; that is, each 
individual could contribute multiple denosumab doses. We used a 6-month “run-in” period (a 
concept borrowed from randomized controlled trials) to assess the eligible injections, which 
should follow a prior dose. Eligible patients should not switch to other antiosteoporosis 
medications and should be alive at the time of follow-up. At the end of the run-in period, a 
subsequent dose should be given and may raise concerns if delayed. We examined the effect of 
delaying the subsequent dose on fracture risk in the 6 months after the run-in period (Appendix 
Figure 1, available at Annals.org). Under the assumption that the effect of delay was similar 
among the second, third, and fourth injections, we pooled their effect estimates. In accordance 
with the clinical practice that patients who have fractures while receiving denosumab are still 
eligible for the treatment, we did not exclude patients who had fractures in the run-in period. 
We set the recommended date of a subsequent dose of denosumab as 6 months after a 
prior dose; thus, it would be given at the end of the run-in period. We compared the effect of 
various delays of the subsequent dose (Appendix Figure 1): “on time,” or within 4 weeks after 
the recommended date; “short delay,” or between 4 and 16 weeks after the recommended 
date; and “long delay,” or more than 16 weeks after the recommended date but not beyond 6 
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months (those who had not received a subsequent dose by the end of follow-up were also 
classified as having a long delay). In clinical practice, patients who receive a subsequent dose 
“early” (that is, 5 to 6 months after the prior dose) are also viewed as having it on time; thus, we 
classified these injections as “on time.” A sensitivity analysis excluding these injections did not 
substantially change the estimates. 
Fracture Outcomes 
We compared fracture risk among the 3 groups during the 6-month follow-up, with a specific 
interest in the fracture trend difference. The primary outcome of interest was composite 
fracture, which included all types of fracture. Secondary outcomes were major osteoporotic 
fracture (hip, vertebral, wrist, humerus, pelvis, and rib), vertebral fracture, hip fracture, and 
nonvertebral fracture (19, 20). We defined fracture outcomes using validated Read codes (19, 
21, 22); positive predictive value was 88.1% for vertebral fracture and 91.0% for hip fracture 
(22–24). Follow-up started the day after the end of the run-in period (Appendix Figure 1) and 
continued until the first of any of the following: a first fracture event, death, a switch to any 
other antiosteoporosis drug, 6 months, or the end of the study (30 April 2019). 
Covariates 
We set the recommended date of a subsequent dose (6 months after a prior dose) as the 
index date and used a 2-year baseline window to pool data for the following variables (Appendix 
Figure 1): sociodemographic factors (for example, age and sex), lifestyle factors (for example, 
smoking and alcohol use), comorbid conditions that are potential risk factors for fracture, 
medications that affect bone metabolism, and antiosteoporosis therapy history (alendronate, 
ibandronate, risedronate, zoledronic acid, teriparatide, other bisphosphonates, and hormone 
replacement therapy). Charlson Comorbidity Index score was calculated with a Read coding 
algorithm (25). Ten-year risk for osteoporotic fracture was calculated using the QFracture 2012 
algorithm (26). In addition, we pooled time-varying covariates measured after baseline at 1-week 
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intervals (Supplement, available at Annals.org). 
Statistical Analysis 
We explicitly emulated a randomized controlled trial comparing 3 groups with various delays 
of subsequent injection. Because the exposure of interest was “exposure duration” (on time vs. 
short delay vs. long delay), we adopted a “cloning, censoring, and weighting” approach to 
estimate the effect of delay duration on time to fracture using observational data (27). We 
created a data set with 3 copies of each eligible injection at baseline and assigned each of the 
replicates to 1 group at the start of follow-up (Appendix Figure 2, available at Annals.org). We 
censored replicates if and when they deviated from the assigned group, ensuring that replicates 
follow their assigned group. However, doing so has the potential to introduce selection bias, 
which we accounted for using time-varying inverse probability weights (27, 28). The 
denominator of the inverse probability weight was the probability that a replicate received his or 
her own observed treatment given his or her covariate history at and after baseline, treatment 
history, and not having a fracture before time t. In addition, we assigned a second time-varying 
inverse probability weight to address the imbalance in other reasons for loss to follow-up. These 
weights created 3 pseudopopulations in which treatment is independent of prognostic factor 
history (the Supplement provides technical details of this method). Differences in fracture events 
between the 3 pseudopopulations approximated the effect of delays of subsequent injections on 
fracture. 
For the relative estimates, we fitted a pooled logistic regression model for each outcome, 
adjusting for baseline confounders in the weighted population (29). Because the outcome was 
rare, the odds ratio from this model approximated the hazard ratio (HR) (28, 30). The linear 
trend of group difference was tested with a continuous indicator of the delay group in the same 
model. We used a robust SE to compute conservative 95% CIs for all of the HR estimates. We 
also estimated absolute risks by fitting the pooled logistic models with product (“interaction”) 
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terms between the delay indicator and the week of follow-up variables. The models’ predicted 
values were then used to estimate the cumulative incidence of fractures from baseline. The 
cumulative incidence curves were standardized to the baseline variables (15). We used a 
nonparametric bootstrap with 500 samples to compute the 95% CIs for absolute estimates. 
To test the robustness of the primary analysis, we did several sensitivity analyses (1). In the 
primary analysis, patients who had a fracture during the run-in period were eligible. However, 
patients with recent fractures have high risk for further fractures and could be more adherent to 
denosumab. The primary analysis could potentially underestimate the fracture risk difference 
between long delay and on time; therefore, we repeated the analysis, excluding patients who 
had fractures during the run-in period (2). Unmeasured confounding (for example, vitamin D or 
calcium, diet, and activity level) may bias the estimates from this observational study; we 
examined this bias using the E-value (31). We did predefined subgroup analyses stratified by age, 
prior duration of bisphosphonate use, and baseline fracture risk to examine fracture risk among 
study groups with different characteristics. In addition, to better evaluate the association 
between injection delay and fracture risk, we did an exploratory analysis in which we extended 3 
groups to 23 groups, representing delay of a subsequent dose by 4 to 26 weeks at 1-week 
increments. Then, we estimated the delay effect by smoothing over the 23 groups using a 
flexible fourth-degree polynomial function (32–34). This analysis allowed us to assess the 
continuous relationship between denosumab injection delay and fracture risk. 
All P values were 2-sided, and P < 0.05 was considered statistically significant for all tests. All 
analyses were done using R, version 3.5.2 (R Foundation), and SAS, version 9.4 (SAS Institute). 
Role of the Funding Source 
This study was funded by the National Institutes of Health and internal resources from the 
National Clinical Research Center for Orthopedics, Sports Medicine & Rehabilitation (Beijing) and 
Xiangya Hospital, Central South University. The funding sources had no role in the design or 
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conduct of the study; collection, management, analysis, or interpretation of the data; 
preparation, review, or approval of the manuscript; or the decision to submit the manuscript for 




We identified 3964 persons who initiated denosumab treatment for osteoporosis between 1 
June 2010 and 30 April 2019. After excluding 1370 of these 3964 initiators who did not complete 
the run-in period, we had a final cohort of 2594 patients. These patients contributed a total of 
6144 qualified denosumab injections (Figure 1) that were used to emulate the target trial; 1856 
of these injections were administered within 4 weeks before the index date (thus belonging only 
to the on-time group), leaving 4288 injections that could be delayed. The study population had a 
low burden of comorbid conditions, but participants were at very high risk for fracture, with a 
mean 10-year risk for major osteoporotic fracture of 22% (Table 1). The mean age at baseline 
was 76 years (SD, 10). Most patients were female (94%), 53% had a history of major osteoporotic 
fracture, 19% had a history of hip fracture, and 15% had had a vertebral fracture. 
Comparative Fracture Risk 
The cumulative risk for composite fracture overlapped for on-time dosing, short delay, and 
long delay (Figure 2); it was 27.3 in 1000 for on time, 32.2 in 1000 for short delay, and 42.4 in 
1000 for long delay over 6 months. The corresponding risk difference between short delay and 
on-time dosing over 6 months was 4.8 (CI, −1.2 to 10.1) in 1000, and the HR was 1.03 (CI, 0.63 to 
1.69). The corresponding risk difference between long delay and on-time dosing over 6 months 
was 15.0 (CI, 1.4 to 33.5) in 1000, and the HR was 1.44 (CI, 0.96 to 2.17). The P value for the 
composite fracture trend difference across the 3 groups was 0.093 (Table 2). The cumulative risk 
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for vertebral fracture over 6 months was 2.2 in 1000 for on-time dosing, 3.6 in 1000 for short 
delay, and 10.1 in 1000 for long delay. The corresponding risk difference between short delay 
and on-time dosing over 6 months was 1.4 (CI, −0.6 to 2.4) in 1000, and the HR was 1.48 (CI, 
0.58 to 3.79). The corresponding risk difference between long delay and on-time dosing over 6 
months was 7.9 (CI, 1.1 to 16.6) in 1000, and the HR was 3.91 (CI, 1.62 to 9.45). Results of the 4 
secondary outcomes are shown in Table 2, Figure 2, and Appendix Figure 3 (available at 
Annals.org). A borderline increase in fracture risk with long delay was seen for major 
osteoporotic fracture, but not for hip or nonvertebral fractures (Table 2). 
Results of sensitivity analyses were similar to those of the primary analysis. For vertebral 
fracture, short delay was associated with a similar fracture risk to on-time dosing; long delay had 
a higher risk than on-time dosing (Appendix Table 2, available at Annals.org). In an analysis 
restricted to patients who did not have fractures in the 6 months before the start of follow-up, 
long delay had a higher risk for fracture than on-time dosing for composite fracture (HR, 1.58 [CI, 
1.04 to 2.41]), major osteoporotic fracture (HR, 2.00 [CI, 1.18 to 3.39]), and vertebral fracture 
(HR, 4.61 [CI, 1.78 to 11.9]) (Table 2). Although sensitivity analyses were somewhat 
underpowered for composite, hip, and nonvertebral fracture, that for vertebral fracture 
suggested that long delay had a higher risk for fracture than on-time dosing, with HRs ranging 
from 3.92 to 6.32 (Appendix Table 2). To examine the effect of unmeasured confounding, we 
found an E-value of 7.28 with a lower confidence limit of 2.62 for vertebral fracture, meaning 
that substantial unmeasured confounding would be needed to explain away the association 
between long delay and vertebral fracture risk to the null. The E-value for composite fracture 
was 2.23, with a lower confidence limit of 1.00 (Appendix Table 3, available at Annals.org). This 
suggests a more robust causal relationship between long delay and vertebral fracture than 
between long delay and composite fracture. We found no statistically significant effect modifier 
when we examined interactions with various patient characteristics (Table 3). In an exploratory 
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analysis examining the continuous dose–response relationship between delay and fracture risk 
(Appendix Figure 4, available at Annals.org), smoothed curves confirmed that risk for fracture 
increased with delay duration. 
Discussion 
Delaying subsequent denosumab doses by more than 4 months was associated with 
increased risk for vertebral fracture compared with on-time injection; however, evidence was 
insufficient to conclude that fracture risk was increased at other anatomical sites with long delay. 
This study suggests the importance of timely denosumab administration when used for long-
term osteoporosis management. Currently, the Endocrine Society (35) and National 
Osteoporosis Foundation (36) recommend that “administration of denosumab should not be 
delayed or stopped without subsequent antiresorptive" (35). However, this recommendation is 
based on an ungraded good practice statement. Our study provides supportive evidence that 
poor adherence is associated with less benefit from denosumab. 
In a previous study, we examined the effect of poor adherence to 6-monthly dosing with 
denosumab on BMD response (11). Patients with good adherence (equivalent to on time) had an 
average BMD increase of 3.9% at the lumbar spine, higher than patients with moderate 
adherence (equivalent to short delay; 2.8%) or poor adherence (equivalent to long delay; 1.6%) 
(P for trend = 0.009). The association was similar for total hip BMD. These results are compatible 
with the current study using fracture end points. Patients who delayed their subsequent dose of 
denosumab by more than 4 months had a 3.91-fold increased risk for vertebral fracture 
compared with those who received it on time. 
Denosumab delay can be viewed as temporary discontinuation; thus, the effect of 
denosumab delay on fracture shares the same mechanism as discontinuation. A previous 
pharmacokinetic study showed that serum denosumab concentration reached its highest level 
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immediately after administration and gradually decreased to less than 100 ng/mL at 6 months 
(37). At the same time, bone resorption biomarker urinary N-telopeptides of type I collagen–
creatinine ratio started to increase at 6 months and returned to the baseline level around 8 to 9 
months in healthy participants (38). However, in the osteoporosis population, bone turnover 
markers increased above the baseline level after 3 months of discontinuation (2). In terms of 
fracture risk, Appendix Figure 4 shows that risk may increase around 10 to 12 weeks after the 
recommended date of the subsequent dose. 
Fracture associated with denosumab withdrawal was first reported in 2016 (4–8), raising 
concerns about increased risk for multiple vertebral fractures after stopping denosumab 
therapy. In a clinical trial population who discontinued denosumab, the vertebral fracture rate 
increased about 5-fold, from 1.2 per 100 participant-years during the on-treatment period to 7.1 
per 100 participant-years (8). In routine clinical settings, denosumab discontinuation (10) was 
associated with 4.7-fold higher risk for vertebral fracture than continuation. Risk also increased 
for major osteoporotic fracture (RR, 3.2 [CI, 2.2 to 4.8]) and hip fracture (RR, 5.3 [CI, 2.0 to 13.9]). 
In this study, we provide evidence that denosumab delay by more than 4 months is sufficient to 
cause a similar increase in vertebral fracture risk, whereas an increased risk for fracture at other 
anatomical sites cannot be ruled out. The risk difference between long delay and on-time doses 
might be underestimated in the current analysis. Estimates from sensitivity analyses excluding 
patients who had fractures in the 6 months before the start of follow-up showed that long delay 
led to higher risk for fracture than on-time administration for composite fracture (HR, 1.58 [CI, 
1.04 to 2.41]), major osteoporotic fracture (HR, 2.00 [CI, 1.18 to 3.39]), and vertebral fracture 
(HR, 4.61 [CI, 1.78 to 11.9]). It might be inappropriate to conclude that risk was increased for all 
of these fractures, except for vertebral fracture, on the basis of these estimates. These results 
came from sensitivity analyses and could have multiple testing problems. However, they at least 
provide us a good motivation for larger studies, which can exclude or confirm such risks. 
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Without a placebo group, this study design cannot tell us whether the elevated fracture risk 
represents a reversal to the pretreatment baseline risk (that is, reduced therapeutic effect) or a 
rebound increase above the baseline (that is, true harm). 
The major strength of this study is that we adopted a target trial emulation design, which 
helps align results from an observational study with those of actual randomized controlled trials 
(14, 39–43). Because the exposure of interest was time-related, we further used rigorous 
analysis methods to establish a correct, temporal, causal relationship between exposure and 
outcome, with exposure (that is, dosing delay) assigned before fracture events, providing a 
robust estimation of the effect of delay on fracture. This study had limited statistical power for 
composite fracture and several secondary end points (CIs were wide and included the null), 
except for vertebral fracture. Thus, evidence was insufficient to conclude that fracture risk was 
increased at other anatomical sites. Future studies with larger sample sizes are needed. Second, 
fracture diagnoses in primary care databases are underrecorded (44). Fracture incidence may be 
underestimated, especially for vertebral fractures. Such measurement bias would be 
nondifferential across study groups and would dilute an association, biasing the observed effect 
toward the null. Third, for each patient, we counted only the first fracture during follow-up, 
which may have led to further underestimation of the delay effect. On the basis of available 
evidence, patients who delay their subsequent injections are more likely to have multiple 
fractures, especially multiple vertebral fractures (8). We examined the occurrence of multiple 
vertebral fractures, but this end point could not be accurately determined in THIN. Future 
prospective studies with a well-adjudicated multiple vertebral fracture end point are needed. 
Fourth, we tried to examine the time course in increased fracture risk after delayed denosumab 
injection (Appendix Figure 4) and found an increase in vertebral fracture up to 24 weeks. 
However, whether this is the peak, plateau, or part of the decline remains unanswered. Fifth, the 
delay patterns were not randomly assigned and were thus susceptible to unmeasured 
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confounding. Such unmeasured confounding would be needed to have a combined effect size in 
excess of 7.28 to reduce the observed association between long delay and vertebral fracture to 
null. Last, reasons for delaying injections were not recorded in THIN; examining these reasons 
may help us develop strategies to improve adherence. 
Although delayed administration of subsequent denosumab doses by more than 16 weeks is 
associated with increased risk for vertebral fracture compared with on-time administration, 
evidence is insufficient to conclude that risk for fracture is increased at other anatomical sites 
with long delay. Because patients who used denosumab were at high risk for vertebral fracture, 
strategies to improve timely administration of denosumab in routine clinical settings are needed. 
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Figure 1. Flow chart of eligible participants and denosumab doses, THIN 2010–2019. We 
compared the outcomes in 3 groups: “on time,” receiving the subsequent dose <4 wk after the 
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recommended date; “short delay,” receiving the subsequent dose 4–16 wk after the 
recommended date; and “long delay,” receiving the subsequent dose >16 wk after the 
recommended date. In clinical practice, patients who receive a subsequent dose “early” (i.e., 4 
wk before the recommended date) are also considered to have received it on time. These 
injections were immediately censored after time 0 for the delay groups. THIN = The Health 
Improvement Network. 
Figure 2. Cumulative risk for fractures. A. The composite fracture risk overlapped for on time, 
short delay, and long delay. Fracture risk increased in the long delay pattern after 20 wk of 
follow-up. Compared with on time, short delay had a fracture risk difference of 4.8/1000 (95% 
CI, −1.2/1000 to 10.1/1000) over 6 mo, with a hazard ratio (HR) of 1.03 (CI, 0.63 to 1.69); long 
delay had a fracture risk difference of 15.0/1000 (CI, 1.4/1000 to 33.5/1000) over 6 mo, with an 
HR of 1.44 (CI, 0.96 to 2.17). B. Compared with on time, short delay had a fracture risk difference 
of 1.4/1000 (CI, −0.6/1000 to 2.4/1000) over 6 mo, with an HR of 1.48 (CI, 0.58 to 3.79); long 
delay had a fracture risk difference of 7.9/1000 (CI, 1.1/1000 to 16.6/1000) over 6 mo, with an 
HR of 3.91 (CI, 1.62 to 9.45). C. Compared with on time, short delay had a fracture risk difference 
of 3.5/1000 (CI, −1.0/1000 to 6.7/1000) over 6 mo, with an HR of 0.94 (CI, 0.57 to 1.55); long 
delay had a fracture risk difference of 12.5/1000 (CI, 2.2/1000 to 26.1/1000) over 6 mo, with an 
HR of 1.69 (CI, 1.01 to 2.83). D. Compared with on time, short delay had a fracture risk difference 
of 0.2/1000 (CI, −2.9/1000 to 2.0/1000) over 6 mo, with an HR of 0.97 (CI, 0.44 to 2.12); long 
delay had a fracture risk difference of 3.7/1000 (CI, −2.3/1000 to 11.9/1000) over 6 mo, with an 
HR of 1.75 (CI, 0.81 to 3.79). 
Appendix Figure 1. Study design of a hypothetical randomized controlled trial (“target trial”) on 
which we modeled our observational data analysis. We conceptualized a target trial comparing 
fracture risk between delays in subsequent dosing. Time 0 was set as the time when the 
subsequent injection should be administrated, with follow-up over the following 6 mo. We 
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compared the effect of 3 groups with different delays of the subsequent dose: “on time,” or 
within 4 wk after the recommended date; “short delay,” or 4–16 wk after the recommended 
date; and “long delay,” or >16 wk after the recommended date. This figure follows the 
recommendation on the visualization of study design from Schneeweiss and colleagues (18). 
Appendix Figure 2. Target trial emulation with “cloning, censoring, and weighting” approach. To 
emulate the target trial in Appendix Figure 1 using observational data, we first created 3 copies 
of each eligible individual at baseline and assigned each of the replicates to each of the groups at 
time 0. Second, we censored replicates if and when they deviated from the assigned group, 
ensuring that replicates follow their assigned group. However, doing so may introduce selection 
bias, which can be eliminated by inverse probability of censoring weights in which uncensored 
observations are upweighted to represent censored observations with similar characteristics. 
The inverse probability of censoring weights 3 pseudopopulations. Differences in fracture events 
between the 3 pseudopopulations approximated the effect of the subsequent injections delay 
on fracture. 
Appendix Figure 3. Cumulative risk for nonvertebral fracture. Compared with on time, short 
delay had a fracture risk difference of 2.9/1000 (95% CI, −3.0/1000 to 8.5/1000) over 6 mo, with 
a hazard ratio (HR) of 0.97 (CI, 0.57 to 1.66); long delay had a fracture risk difference of 8.6/1000 
(CI, −4.1/1000 to 24.2/1000) over 6 mo, with an HR of 1.25 (CI, 0.80 to 1.94). 
Appendix Figure 4. Association between delayed weeks and risk for fracture. Continuous dose–
response relationship between delay and fracture risk. The x-axis represents subsequent dosing 
delay of 4–26 wk at weekly increments; the y-axis is the estimated hazard ratio of serial delay 
patterns with on-time dosing as the reference. Smoothed curves are used to show the 
association between weeks delayed and fracture risk. 
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Table 1. Baseline Characteristics of Participants* 
 
Characteristic Study Population (n 
= 2594) 
Mean age (SD), y 75.8 (9.5) 
Women  2450 (94.4)  
Mean BMI (SD), kg/m2 24.5 (5.3) 
Smoking status   
Current   248 (9.6)  
None  1625 (62.9)  
Past   710 (27.5)  
Cerebrovascular disease    75 (2.9)  
Chronic pulmonary disease   148 (5.7)  
Dementia    79 (3.0)  
Diabetes    78 (3.0)  
Peptic ulcer disease     9 (0.3)  
Myocardial infarction    26 (1.0)  
Peripheral vascular disease    21 (0.8)  
Renal disease   121 (4.7)  
Any cancer    60 (2.3)  
Parkinson disease    19 (0.7)  
Rheumatoid arthritis    36 (1.4)  
Mean Charlson Comorbidity Index score (SD)  0.39 (0.80) 
History of major osteoporotic fracture  1364 (52.6)  
History of hip fracture   487 (18.8)  
History of spine fracture   396 (15.3)  
Mean 10-y risk for major osteoporotic fracture 
(SD), %† 22.0 (15.5) 
Mean 10-y risk for hip fracture (SD), %† 18.7 (19.8) 
Mean duration of oral bisphosphonate use (SD), y  3.1 (3.6) 
Medication use  
Intravenous bisphosphonates     7 (0.3)  
Hormone replacement therapy    50 (1.9)  
SERMs    12 (0.5)  
Teriparatide     4 (0.2)  
Tricyclic antidepressant   382 (14.7)  
Antiepilepsy drug   321 (12.4)  
Systemic corticosteroids   538 (20.7)  
Benzodiazepine   425 (16.4)  
NSAIDs  1453 (56.0)  
Opioids   820 (31.6)  
PPI  1429 (55.1)  
SSRI   372 (14.3)  
Mean number of hospitalizations (SD)  1.8 (2.8) 
Mean number of primary care visits (SD) 17.9 (15.1) 
Mean number of referrals to the hospital (SD)  2.2 (2.3) 
 
BMI = body mass index; NSAID = nonsteroidal anti-inflammatory drug; PPI = proton-pump inhibitor; 
SERM = selective estrogen receptor modulator; SSRI = selective serotonin reuptake inhibitor. 
 
* Values are numbers (percentages) unless otherwise specified. 
† Less than 1% of values were missing for BMI, race, and smoking history. To calculate the 
QFracture score, missing values were imputed by a sequential regression method based on 




Table 2. Frequency, Rates, and Adjusted HRs of Fracture for On Time, Short Delay, and Long 
Delay Between Denosumab Doses* 
 
Variable On Time Short Delay Long Delay P for 
Trend 
Composite fractures† 
    
Weighted persons, n‡ 8282 6771 6319  
Weighted events, n‡ 243 208 269  
Risk over 6 mo (95% CI), per 
1000 
27.3 (19.1 to 36.2) 32.2 (24.1 to 43.5) 42.4 (27.7 to 64.6)  
Risk difference over 6 mo 
(95% CI), per 1000 
Reference 4.8 (−1.2 to 10.1) 15.0 (1.4 to 33.5)  
Fully adjusted HR (95% CI)§ Reference 1.03 (0.63 to 1.69) 1.44 (0.96 to 2.17) 0.093 
Sensitivity analysis HR (95% 
CI)|| 
Reference 1.07 (0.63 to 1.82) 1.58 (1.04 to 2.41) 0.040 
     
Major osteoporotic fractures† 
    
Weighted persons, n‡ 8316 6813 6348  
Weighted events, n‡ 144 108 184  
Risk over 6 mo (95% CI), per 
1000 
14.7 (9.6 to 18.6) 18.1 (12.7 to 21.9) 27.4 (17.4 to 39.2)  
Risk difference over 6 mo 
(95% CI), per 1000 
Reference 3.5 (−1.0 to 6.7) 12.5 (2.2 to 26.1)  
Fully adjusted HR (95% CI)§ Reference 0.94 (0.57 to 1.55) 1.69 (1.01 to 2.83) 0.056 
Sensitivity analysis HR (95% 
CI)|| 
Reference 1.02 (0.60 to 1.73) 2.00 (1.18 to 3.39) 0.013 
     
Vertebral fractures 
    
Weighted persons, n‡ 8361 6984 6409  
Weighted events, n‡ 21 25 62  
Risk over 6 mo (95% CI), per 
1000 
2.2 (1.1 to 3.6) 3.6 (1.6 to 5.4) 10.1 (3.5 to 19.1)  
Risk difference over 6 mo 
(95% CI), per 1000 
Reference 1.4 (−0.6 to 2.4) 7.9 (1.1 to 16.6)  
Fully adjusted HR (95% CI)§ Reference 1.48 (0.58 to 3.79) 3.91 (1.62 to 9.45) 0.005 
Sensitivity analysis HR (95% 
CI)|| 
Reference 1.67 (0.60 to 4.62) 4.61 (1.78 to 11.9) 0.003 
     
Hip fractures 
    
Weighted persons, n‡ 8352 6934 6399  
Weighted events, n‡ 43 33 58  
Risk over 6 mo (95% CI), per 
1000 
4.8 (2.7 to 7.1) 5.0 (2.4 to 6.9) 8.5 (3.3 to 16.1)  
Risk difference over 6 mo 
(95% CI), per 1000 
Reference 0.2 (−2.9 to 2.0) 3.7 (−2.3 to 11.9)  
Fully adjusted HR (95% CI)§ Reference 0.97 (0.44 to 2.12) 1.75 (0.81 to 3.79) 0.173 
Sensitivity analysis HR (95% 
CI)|| 
Reference 1.02 (0.45 to 2.33) 1.91 (0.86 to 4.26) 0.132 
     
Nonvertebral fractures 
    
Weighted persons, n‡ 8286 6771 6329  
Weighted events, n‡ 229 185 219  
Risk over 6 mo (95% CI), per 
1000 
25.8 (18.3 to 35.1) 28.7 (20.6 to 39.4) 34.4 (21.2 to 52.9)  
Risk difference over 6 mo 
(95% CI), per 1000 
Reference 2.9 (−3.0 to 8.5) 8.6 (−4.1 to 24.2)  
Fully adjusted HR (95% CI)§ Reference 0.97 (0.57 to 1.66) 1.25 (0.80 to 1.94) 0.35 
Sensitivity analysis HR (95% 
CI)|| 




HR = hazard ratio. 
 
* We compared the outcomes in 3 groups: “on time” indicates that the subsequent dose was received 
within 4 wk after the recommended date, “short delay” that the subsequent dose was received 4–16 
wk after the recommended date, and “long delay” that the subsequent dose was received >16 wk 
after the recommended date.  
† Composite fractures were fractures at any site. Major osteoporotic fractures included hip fracture, 
vertebral fracture, wrist fracture, humerus fracture, pelvis fracture, and rib fracture.  
‡ Persons and events were calculated in the weighted population. 
§ HRs were calculated from the final model, adjusting for baseline and postbaseline covariates; we 
used a robust SE to compute conservative 95% CIs for all of the HR estimates. 
|| This model was the same as the primary analysis model, except that patients who had fractures in 




Table 3. Subgroup Analyses, Stratified by Age, Prior Length of BP Use, and 10-Year Risk for 
Major Osteoporotic Fracture* 
 
 
Variable HR (95% CI) for 
Short Delay† 







    
Stratified by age 
   
0.56 
>75 y 1.14 (0.58–2.25) 1.58 (0.94–2.64) 0.091  
≤75 y 0.96 (0.52–1.80) 1.20 (0.59–2.43) 0.63  
Stratified by length of prior 
oral BP use 
   
0.76 
≤3 y 1.18 (0.58–2.38) 1.75 (1.01–3.03) 0.053  
>3 y 0.96 (0.54–1.70) 1.16 (0.61–2.21) 0.67  





Fracture risk >20% 1.29 (0.66–2.52) 1.64 (0.92–2.90) 0.094  
Fracture risk ≤20% 0.72 (0.42–1.25) 1.22 (0.67–2.24) 0.57  
     
Major osteoporotic 
fractures 
   
 
Stratified by age 
   
0.165 
>75 y 0.84 (0.44–1.62) 2.11 (1.12–3.96) 0.028  
≤75 y 1.18 (0.53–2.61) 1.07 (0.44–2.63) 0.85  
Stratified by length of prior 
oral BP use 
   
0.48 
≤3 y 1.06 (0.52–2.16) 2.03 (0.99–4.14) 0.058  
>3 y 0.89 (0.44–1.80) 1.30 (0.60–2.82) 0.53  





Fracture risk >20% 1.10 (0.52–2.35) 2.36 (1.13–4.95) 0.028  
Fracture risk ≤20% 0.79 (0.40–1.58) 1.21 (0.57–2.55) 0.66  
     
Vertebral fractures 
   
0.55 
Stratified by age 
   
 
>75 y 1.17 (0.27–5.09) 4.09 (1.17–14.3) 0.038  
≤75 y 2.07 (0.61–6.99) 3.39 (0.96–12.0) 0.082  
Stratified by length of prior 
oral BP use 
   
0.31 
≤3 y 1.49 (0.44–5.08) 4.83 (1.68–13.9) <0.001  
>3 y 1.73 (0.39–7.63) 1.83 (0.33–10.2) 0.50  





Fracture risk >20% 2.08 (0.44–9.73) 3.62 (0.75–17.4) 0.142  
Fracture risk ≤20% 1.21 (0.37–3.97) 4.52 (1.64–12.5) 0.008  
     
Hip fractures 
   
 
Stratified by age 
   
0.51 
>75 y 0.61 (0.21–1.79) 2.03 (0.76–5.45) 0.189  
≤75 y 1.82 (0.55–6.00) 1.51 (0.42–5.44) 0.47  
Stratified by length of prior 
oral BP use 
   
0.76 
≤3 y 1.57 (0.58–4.30) 2.31 (0.81–6.58) 0.127  
>3 y 0.51 (0.12–2.07) 1.51 (0.47–4.87) 0.55  





Fracture risk >20% 1.66 (0.50–5.53) 4.08 (1.39–12.0) 0.015  
Fracture risk ≤20% 0.69 (0.24–2.01) 0.73 (0.22–2.43) 0.58  
     
Nonvertebral fractures 
   
0.77 
Stratified by age 
   
 
>75 y 1.10 (0.54–2.27) 1.32 (0.76–2.30) 0.33  
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≤75 y 0.83 (0.42–1.65) 1.12 (0.52–2.41) 0.81  
Stratified by length of prior 
oral BP use 
   0.50 
≤3 y 1.11 (0.52–2.36) 1.46 (0.80–2.66) 0.23  
>3 y 0.88 (0.47–1.63) 1.07 (0.54–2.12) 0.86  





Fracture risk >20% 1.23 (0.60–2.51) 1.62 (0.90–2.91) 0.114  
Fracture risk ≤20% 0.65 (0.36–1.18) 0.83 (0.40–1.72) 0.57 
 
 
BP = bisphosphonate. 
 
* We compared the outcomes in 3 groups: “on time” indicates that the subsequent dose was received within 4 
wk after the recommended date, “short delay” that the subsequent dose was received 4–16 wk after the 
recommended date, and “long delay” that the subsequent dose was received >16 wk after the recommended 
date. 
† The reference group was on-time dosing. 






Appendix Table 1. Specification and Emulation of a Target Trial of Denosumab Delay and Fracture 




Target Pragmatic Trial Specification (A 
Hypothetical RCT That Is Ideal for 
Answering This Question) 
Target Trial Emulation (Using 
Observational Data to Best 
Approximate the RCT 
Comparison) 
Eligibility criteria We set a 6-mo (180-d) “run-in” period to 
assess eligibility. 
Age ³45 y between 2010 and 2019. 
Received a prior dose of denosumab 180 
d before. 
Did not receive any other antiosteoporosis 
drug in the prior 180 d. 
≥1 y of up-to-standard data in a THIN 
primary care practice. 
Same as the target trial, except 
that patients could be eligible 
multiple times. Thus, we will 
emulate sequential trials and 
combine them. 
We will collect baseline covariates 
during the past 2 y. 
Treatment 
strategies 
1) On time: receive a subsequent dose of 
denosumab within 4 wk after 
randomization. 
2) Short delay: receive a dose of 
denosumab 4–16 wk after randomization. 
3) Long delay: receive a dose of 
denosumab >16 wk after randomization. 
In the 3 strategies, patients are not 
allowed to switch to any other 
antiosteoporosis drug (i.e., estrogens, 
selective estrogen receptor modulators, 
bisphosphonates, teriparatide, or 
combination of these medications). 
Same as for the target trial. 
We define the date of denosumab 
injection using the date of 
denosumab prescription. In clinical 
practice, subsequent doses 
received early (i.e., 5–6 mo after 
the prior dose) are also viewed as 
on time. We will classify these 
injections as "on time" in the 
primary analysis and exclude them 
in the sensitivity analysis. 
Treatment 
assignment 
Eligible individuals are randomly assigned 
to 1 of the 3 “treatment strategies” and 
are aware of the strategy to which they 
have been assigned. 
We classified patients according to 
the strategy that their data were 
comparable with at time 0 and 
emulated randomization by 
adjusting for baseline 
confounders. 
Outcomes Composite fracture (including all types of 
fracture), major osteoporotic fracture (hip, 
vertebral, wrist, humerus fracture, pelvis, 
and rib fracture), vertebral fracture, and 
hip fracture. 
Same as for the target trial. 
Follow-up Starts at the time of assignment to a 
strategy and ends at the earliest of first 
fracture, death, 6 mo after time 0, or 
administrative end of follow-up. 
Starts the day after the end of the 
“run-in” period. 





Per protocol effect (45): censor patients 
when they deviate from their assigned 
treatment strategy (not follow the 
predefined protocol, die, or switch/add 
other osteoporosis medications). The 
analysis will adjust for prerandomization 
and postrandomization prognostic factors 
that predict adherence to the protocol and 
loss to follow-up. 
Observational analogue of the per 
protocol effect: same as target 
trial, except that we created 3 
individuals (clones) per eligible 
person and assigned 1 to each 
treatment strategy. The analysis 
will adjust for baseline and 
postbaseline prognostic factors 
that predict adherence to the 
protocol and loss to follow-up. 
 




Appendix Table 2. Results of Sensitivity Analyses 
 
Variable HR (95% CI) for 
Short Delay* 
HR (95% CI) for 
Long Delay* 
P for Linear 
Trend 
Composite fractures 
   
Weighted model† 1.04 (0.64–1.71) 1.46 (0.96–2.20) 0.081 
No fracture during run-in period‡ 1.14 (0.65–1.97) 1.64 (1.06–2.53) 0.031 
Additional IPW§ 1.05 (0.63–1.76) 1.47 (0.96–2.24) 0.080 
Delay <6 mo|| 0.96 (0.64–1.45) 1.41 (0.85–2.33) 0.183 
Effect of the second dose¶ 0.67 (0.36–1.34) 1.45 (0.75–2.80) 0.30 
Early injections excluded** 0.98 (0.51–1.88) 1.36 (0.82–2.26) 0.25 
    
Major osteoporotic fractures 
   
Weighted model† 0.95 (0.57–1.58) 1.71 (1.02–2.87) 0.042 
No fracture during run-in period‡ 1.03 (0.61–1.76) 2.03 (1.18–3.50) 0.012 
Additional IPW§ 0.91 (0.55–1.56) 1.66 (0.97–2.83) 0.061 
Delay <6 mo|| 1.04 (0.61–1.76) 1.75 (0.96–3.18) 0.076 
Effect of the second dose¶ 0.96 (0.48–1.91) 2.45 (1.21–4.93) 0.019 
Early injections excluded** 0.81 (0.43–1.52) 1.56 (0.82–2.98) 0.182 
    
Vertebral fractures 
   
Weighted model† 1.49 (0.59–3.77) 3.92 (1.63–9.44) 0.007 
No fracture during run-in period‡ 1.70 (0.63–4.63) 4.73 (1.80–12.5) 0.005 
Additional IPW§ 1.45 (0.57–3.66) 3.95 (1.59– 9.86) 0.008 
Delay <6 mo|| 1.94 (0.72–5.22) 6.32 (2.40–16.6) 0.001 
Effect of the second dose¶ 1.08 (0.25–4.63) 4.05 (1.06–15.4) 0.057 
Early injections excluded** 1.87 (0.64–5.44) 5.37 (1.89–15.3) 0.003 
    
Hip fractures 
   
Weighted model† 1.01 (0.46–2.22) 1.85 (0.85–4.00) 0.134 
No fracture during run-in period‡ 1.03 (0.46–2.31) 2.00 (0.87–4.58) 0.116 
Additional IPW§ 0.97 (0.44–2.15) 1.78 (0.80–3.96) 0.169 
Delay <6 mo|| 1.17 (0.54–2.56) 2.09 (0.87–5.04) 0.12 
Effect of the second dose¶ 0.81 (0.26–2.49) 1.98 (0.62–6.33) 0.28 
Early injections excluded** 0.87 (0.38–1.97) 1.72 (0.74–3.97) 0.22 
    
Nonvertebral fractures 
   
Weighted model† 0.98 (0.57–1.68) 1.26 (0.81–1.97) 0.31 
No fracture during run-in period‡ 1.09 (0.60–1.97) 1.41 (0.88–2.25) 0.16 
Additional IPW§ 1.00 (0.57–1.74) 1.28 (0.81–2.02) 0.28 
Delay <6 mo|| 0.87 (0.56–1.34) 1.08 (0.62–1.90) 0.77 
Effect of the second dose¶ 0.64 (0.33–1.23) 1.20 (0.58–2.48) 0.67 
Early injections excluded** 0.90 (0.45–1.82) 1.13 (0.66–1.95) 0.65 
 
HR = hazard ratio; IPW = inverse probability weight. 
 
* The reference group was on-time dosing. 
† We used inverse probability treatment weights instead of multivariate regression to control potential 
baseline confounding. 
‡ A sensitivity analysis that excluded patients who had fractures during the run-in period. 
§ A sensitivity analysis that used additional inverse probability of censoring weights to address 
potential bias due to attrition of later doses. In our study population, only a proportion of the 2594 
patients received the third dose (79%) and fourth dose (59%). Because of the concern of potential 
selection bias of patients attrition in the later emulated trials, we used an additional IPW to address 
potential bias. 
|| A sensitivity analysis done in a subset population who received their subsequent injection in 6 mo. 
¶ A sensitivity analysis that examined the relationship between delay and fracture risk of the second 
dose only. 




Appendix Table 3. Examining the Effect of Unmeasured Confounding With E-values 
 




of the CI 
Composite fractures 
   
HR (95% CI) 1.44 (0.96 to 2.17) 2.23 1.00 
Sensitivity analysis HR (95% CI) 1.58 (1.04 to 2.41) 2.54 1.24 
    
Major osteoporotic fractures 
   
HR (95% CI) 1.69 (1.01 to 2.83) 2.77 1.11 
Sensitivity analysis HR (95% CI) 2.00 (1.18 to 3.39) 3.41 1.64 
    
Vertebral fractures 
   
HR (95% CI) 3.91 (1.62 to 9.45) 7.28 2.62 
Sensitivity analysis HR (95% CI) 4.61 (1.78 to 11.9) 8.69 2.96 
    
Hip fractures 
   
HR (95% CI) 1.75 (0.81 to 3.79) 2.90 1.00 
Sensitivity analysis HR (95% CI) 1.91 (0.86 to 4.26) 3.23 1.00 
    
Nonvertebral fractures 
   
HR (95% CI) 1.25 (0.80 to 1.94) 1.81 1.00 
Sensitivity analysis HR (95% CI) 1.36 (0.86 to 2.15) 2.06 1.00 
 
CI = confidence interval; HR = hazard ratio. 
 
* The reference group was on-time dosing. 
† The E-value is defined as the minimum strength of association, on the risk ratio scale, that an 
unmeasured confounder would need to have to fully explain away a specific treatment–outcome 
association, conditional on the measured covariates. A large E-value indicates that considerable 
unmeasured confounding would be needed to explain away an effect estimate (31). We found an E-
value of 7.28 with a lower confidence limit of 2.62 for vertebral fracture, meaning that a substantial 
unmeasured confounding is needed to explain away the association between long delay and vertebral 
fracture risk to null. The E-value for composite fracture was 2.23, with a lower confidence limit of 1.00. 
This suggests a more robust causal relationship between long delay and vertebral fracture than 
















































Supplement figure 4 
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